Bristol-Myers Squibb(CH:BMY)
CHFÂ 51.18+0.02 (+0.04%)
CH:BMY
Bristol-Myers Squibb stock forecast
CHFÂ 51.18
At close:+0.02 (+0.04%)
Bristol-Myers Squibb (BMY) Stock Forecast & Price Target
2 Followers
BMY Analyst Ratings
Moderate Buy
8Buy11Hold1Sell
Based on 20 analysts giving stock ratings to Bristol-Myers Squibb in the past 3 months
BMY Stock 12 Month Forecast
Average Price Target
CHF53.88â–²(5.28% Upside)Based on 20 Wall Street analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is CHF 53.88 with a high forecast of CHF 65.57 and a low forecast of CHF 32.79. The average price target represents a 5.28% change from the last price of CHF 51.18.
Past 12 Months12 Month ForecastJan2026Oct2026
HighCHF65.57
AverageCHF53.88
LowCHF32.79
Highest Price TargetHighestCHF65.57Average Price TargetCHF53.88Lowest Price TargetLowestCHF32.79
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Evan Seigerman | BMO Capital | CHF49.18 | hold | -3.91%Downside | Reiterated | 11/09/26 | ||
| Trung Huynh | RBC Capital | CHF52.46 | hold | 2.49%Upside | Reiterated | 11/05/26 | ||
| Courtney Breen | Bernstein | CHF50.00 | hold | -2.31%Downside | Reiterated | 11/02/26 | ||
| Louise Chen | Scotiabank | CHF49.18 | hold | -3.91%Downside | Reiterated | 10/30/26 | ||
| Terence Flynn | Morgan Stanley | CHF33.60→CHF32.79 | sell | -35.94%Downside | Reiterated | 10/30/26 | ||
| Mohit Bansal | Wells Fargo | CHF53.28→CHF49.18 | hold | -3.91%Downside | Reiterated | 10/30/26 | ||
| Emily Field | Barclays | CHF61.47 | buy | 20.11%Upside | Reiterated | 10/29/26 | ||
| Matt Phipps | William Blair | ― | hold | ― | Reiterated | 10/29/26 | ||
| Jason Gerberry | Bank of America Securities | CHF54.10→CHF54.92 | buy | 7.30%Upside | Reiterated | 10/29/26 | ||
| Seamus Fernandez | Guggenheim | CHF61.47 | buy | 20.11%Upside | Reiterated | 10/29/26 | ||
| Carter Gould | Cantor Fitzgerald | CHF43.44 | hold | -15.12%Downside | Reiterated | 10/29/26 | ||
| David Amsellem | Piper Sandler | CHF63.93 | buy | 24.91%Upside | Reiterated | 10/27/26 | ||
| Asad Haider | Goldman Sachs | CHF51.64 | hold | 0.89%Upside | Assigned | 10/19/26 | ||
| Geoff Meacham | Citi | CHF57.37 | hold | 12.10%Upside | Reiterated | 10/13/26 | ||
| Srikripa Devarakonda | Truist Financial | CHF57.37 | buy | 12.10%Upside | Reiterated | 10/13/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Evan SeigermanBMO Capital | HoldReiteratedCHF49.18 | 11/09/26 | -3.91%Downside | ||
| Trung HuynhRBC Capital | HoldReiteratedCHF52.46 | 11/05/26 | 2.49%Upside | ||
| Courtney BreenBernstein | HoldReiteratedCHF50.00 | 11/02/26 | -2.31%Downside | ||
| Louise ChenScotiabank | HoldReiteratedCHF49.18 | 10/30/26 | -3.91%Downside | ||
| Terence FlynnMorgan Stanley | SellReiteratedCHF33.60→CHF32.79 | 10/30/26 | -35.94%Downside | ||
| Mohit BansalWells Fargo | HoldReiteratedCHF53.28→CHF49.18 | 10/30/26 | -3.91%Downside | ||
| Emily FieldBarclays | BuyReiteratedCHF61.47 | 10/29/26 | 20.11%Upside | ||
| Matt PhippsWilliam Blair | HoldReiterated | 10/29/26 | ― | ||
| Jason GerberryBank of America Securities | BuyReiteratedCHF54.10→CHF54.92 | 10/29/26 | 7.30%Upside | ||
| Seamus FernandezGuggenheim | BuyReiteratedCHF61.47 | 10/29/26 | 20.11%Upside | ||
| Carter GouldCantor Fitzgerald | HoldReiteratedCHF43.44 | 10/29/26 | -15.12%Downside | ||
| David AmsellemPiper Sandler | BuyReiteratedCHF63.93 | 10/27/26 | 24.91%Upside | ||
| Asad HaiderGoldman Sachs | HoldAssignedCHF51.64 | 10/19/26 | 0.89%Upside | ||
| Geoff MeachamCiti | HoldReiteratedCHF57.37 | 10/13/26 | 12.10%Upside | ||
| Srikripa DevarakondaTruist Financial | BuyReiteratedCHF57.37 | 10/13/26 | 12.10%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Bristol-Myers Squibb
3 Months
Success Rate13/17 ratings generated profit
76%
Average Return
+9.64%
Copying Srikripa Devarakonda's trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +9.64% per trade.
1 Year
Success Rate11/13 ratings generated profit
85%
Average Return
+19.59%
Copying David Amsellem's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +19.59% per trade.
2 Years
Success Rate16/17 ratings generated profit
94%
Average Return
+28.37%
Copying Srikripa Devarakonda's trades and holding each position for 2 Years would result in 94.12% of your transactions generating a profit, with an average return of +28.37% per trade.
BMY Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 22 | 21 | 16 | 20 | 14 |
| Hold | 30 | 28 | 33 | 39 | 33 |
| Sell | 2 | 2 | 3 | 5 | 4 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 54 | 51 | 52 | 64 | 51 |
In the current month, BMY has received 14 Buy Ratings, 33 Hold Ratings, and 4 Sell Ratings. BMY average Analyst price target in the past 3 months is 53.88.
BMY Financial Forecast
HighCHF1.36
ConsensusCHF1.25
LowCHF1.10
BMY Earnings Forecast
Next quarter’s earnings estimate for BMY is CHF 1.25 with a range of CHF 1.10 to CHF 1.36. The previous quarter’s EPS was CHF 1.12. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighCHF10.8B
ConsensusCHF10.5B
LowCHF10.3B
BMY Sales Forecast
Next quarter’s sales forecast for BMY is CHF 10.54B with a range of CHF 10.34B to CHF 10.84B. The previous quarter’s sales results were CHF 10.88B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
BMY Stock Forecast FAQ
What is CH:BMY’s average 12-month price target, according to analysts?
Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is CHF53.88.
What is CH:BMY’s upside potential, based on the analysts’ average price target?
Bristol-Myers Squibb has 5.28% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Bristol-Myers Squibb a Buy, Sell or Hold?
Bristol-Myers Squibb has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 11 hold ratings and 1 sell ratings.
What is Bristol-Myers Squibb’s share price target?
The average share price target for Bristol-Myers Squibb is CHF53.88. This is based on 20 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF65.57, and the lowest forecast is CHF32.79. The average share price target represents a 5.28% increase from the current price of CHF51.18.
What do analysts say about Bristol-Myers Squibb?
Bristol-Myers Squibb’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Street analysts.
How can I buy shares of Bristol-Myers Squibb?
To buy shares of CH:BMY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
